Logo image of SNPX

SYNAPTOGENIX INC (SNPX) Stock Fundamental Analysis

NASDAQ:SNPX - Nasdaq - US87167T3005 - Common Stock - Currency: USD

2.41  -0.28 (-10.41%)

Fundamental Rating

2

SNPX gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 559 industry peers in the Biotechnology industry. While SNPX has a great health rating, there are worries on its profitability. SNPX is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

SNPX had negative earnings in the past year.
SNPX had a negative operating cash flow in the past year.
In the past 5 years SNPX always reported negative net income.
In the past 5 years SNPX always reported negative operating cash flow.
SNPX Yearly Net Income VS EBIT VS OCF VS FCFSNPX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M

1.2 Ratios

Looking at the Return On Assets, with a value of -84.58%, SNPX is doing worse than 72.09% of the companies in the same industry.
Looking at the Return On Equity, with a value of -201.09%, SNPX is doing worse than 68.34% of the companies in the same industry.
Industry RankSector Rank
ROA -84.58%
ROE -201.09%
ROIC N/A
ROA(3y)-45.16%
ROA(5y)-79.02%
ROE(3y)-90%
ROE(5y)-120.41%
ROIC(3y)N/A
ROIC(5y)N/A
SNPX Yearly ROA, ROE, ROICSNPX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150 -200 -250

1.3 Margins

SNPX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SNPX Yearly Profit, Operating, Gross MarginsSNPX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024

More info and screens

7

2. Health

2.1 Basic Checks

The number of shares outstanding for SNPX has been increased compared to 1 year ago.
The number of shares outstanding for SNPX has been increased compared to 5 years ago.
SNPX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
SNPX Yearly Shares OutstandingSNPX Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 200K 400K 600K 800K 1M
SNPX Yearly Total Debt VS Total AssetsSNPX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

2.2 Solvency

Based on the Altman-Z score of -4.21, we must say that SNPX is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -4.21, SNPX is in line with its industry, outperforming 44.54% of the companies in the same industry.
SNPX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -4.21
ROIC/WACCN/A
WACCN/A
SNPX Yearly LT Debt VS Equity VS FCFSNPX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M 30M

2.3 Liquidity

A Current Ratio of 72.70 indicates that SNPX has no problem at all paying its short term obligations.
SNPX has a Current ratio of 72.70. This is amongst the best in the industry. SNPX outperforms 99.82% of its industry peers.
SNPX has a Quick Ratio of 72.70. This indicates that SNPX is financially healthy and has no problem in meeting its short term obligations.
SNPX's Quick ratio of 72.70 is amongst the best of the industry. SNPX outperforms 99.82% of its industry peers.
Industry RankSector Rank
Current Ratio 72.7
Quick Ratio 72.7
SNPX Yearly Current Assets VS Current LiabilitesSNPX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

More info and screens

1

3. Growth

3.1 Past

SNPX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 73.75%, which is quite impressive.
EPS 1Y (TTM)73.75%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%129.54%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

SNPX is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 2.96% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-14.17%
EPS Next 2Y2.96%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
SNPX Yearly EPS VS EstimatesSNPX Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 -10 -20 -30 -40 -50

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for SNPX. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SNPX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SNPX Price Earnings VS Forward Price EarningsSNPX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SNPX Per share dataSNPX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -5

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y2.96%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

SNPX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SYNAPTOGENIX INC

NASDAQ:SNPX (6/6/2025, 8:00:02 PM)

2.41

-0.28 (-10.41%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-27 2025-03-27/amc
Earnings (Next)N/A N/A
Inst Owners1.28%
Inst Owner Change0%
Ins Owners0.67%
Ins Owner Change0%
Market Cap3.35M
Analysts82.86
Price Target14.28 (492.53%)
Short Float %0.32%
Short Ratio0.36
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0.82
Dividend Growth(5Y)N/A
DP-8.16%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.52
P/tB 0.52
EV/EBITDA N/A
EPS(TTM)-9.81
EYN/A
EPS(NY)-7.17
Fwd EYN/A
FCF(TTM)-3.64
FCFYN/A
OCF(TTM)-3.64
OCFYN/A
SpS0
BVpS4.64
TBVpS4.64
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -84.58%
ROE -201.09%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-45.16%
ROA(5y)-79.02%
ROE(3y)-90%
ROE(5y)-120.41%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 72.7
Quick Ratio 72.7
Altman-Z -4.21
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)73.75%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%129.54%
EPS Next Y-14.17%
EPS Next 2Y2.96%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y12.63%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y46.42%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y46.37%
OCF growth 3YN/A
OCF growth 5YN/A